Klarquist Sparkman, LLP
CDK-inhibiting pyrrolopyrimidine carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing the same as active ingredient for preventing or treating hepatocellular carcinoma
The present invention relates to a CDK-inhibiting pyrrolopyrimidine carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating liver cell cancer. Compositions comprising a pyrrolopyrimidine carboxamide derivative of the present invention suppress the cell growth of SNU-354 cell, which is a liver cancer stem cell in humans, by inhibiting CDK1 and CDK2, and induces cell apoptosis of the cell by inhibiting CDK7 and CDK 7. Such compositions are useful for preventing or treating liver cell cancer.
SNU R&DB Foundation
A A C C A
A61K A61P C07H C07H A61K
inventional inventional inventional inventional inventional
Seung Ju Byeong Moon Young Jong Seung Ki
Cho Kim Kim Lee